{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T07:39:51Z","timestamp":1793691591207,"version":"4.5.1"},"reference-count":48,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,6]],"date-time":"2022-09-06T00:00:00Z","timestamp":1662422400000},"content-version":"vor","delay-in-days":370,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002424","name":"Fujifilm Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002424","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010793","name":"Pfizer Japan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010793","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002973","name":"Daiichi-Sankyo","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002973","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007132","name":"Otsuka Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007132","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004823","name":"Nagoya University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004823","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016579","name":"Amgen Astellas Biopharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016579","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004948","name":"Astellas Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004948","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010795","name":"Chugai Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010795","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004095","name":"Kyowa Hakko Kirin","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004095","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003769","name":"Eisai","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003769","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["18k08351"],"award-info":[{"award-number":["18k08351"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["15k09497"],"award-info":[{"award-number":["15k09497"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["15ck0106067h0002"],"award-info":[{"award-number":["15ck0106067h0002"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["17ck0106291h0001"],"award-info":[{"award-number":["17ck0106291h0001"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["19ek0510022h0003"],"award-info":[{"award-number":["19ek0510022h0003"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015990","name":"Sanofi K.K.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015990","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004508","name":"Prince of Songkla University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004508","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006436","name":"Celgene","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.ymthe.2021.04.038","type":"journal-article","created":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T03:04:25Z","timestamp":1619838265000},"page":"2677-2690","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":49,"title":["Composite CD79A\/CD40 co-stimulatory endodomain enhances CD19CAR-T cell proliferation and survival"],"prefix":"10.1016","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6526-9479","authenticated-orcid":false,"given":"Jakrawadee","family":"Julamanee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1194-8046","authenticated-orcid":false,"given":"Seitaro","family":"Terakura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3459-0478","authenticated-orcid":false,"given":"Koji","family":"Umemura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9763-5533","authenticated-orcid":false,"given":"Yoshitaka","family":"Adachi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0716-1424","authenticated-orcid":false,"given":"Kotaro","family":"Miyao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7477-0986","authenticated-orcid":false,"given":"Shingo","family":"Okuno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3983-6871","authenticated-orcid":false,"given":"Erina","family":"Takagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3530-7817","authenticated-orcid":false,"given":"Toshiyasu","family":"Sakai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Koyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0314-9498","authenticated-orcid":false,"given":"Tatsunori","family":"Goto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Hanajiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Hudecek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6848-4097","authenticated-orcid":false,"given":"Peter","family":"Steinberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7156-1759","authenticated-orcid":false,"given":"Judith","family":"Leitner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuya","family":"Nishida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Murata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6382-9498","authenticated-orcid":false,"given":"Hitoshi","family":"Kiyoi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2021.04.038_bib1","doi-asserted-by":"crossref","first-page":"177ra38","DOI":"10.1126\/scitranslmed.3005930","article-title":"CD19-targeted T\u00a0cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia","volume":"5","author":"Brentjens","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymthe.2021.04.038_bib2","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","article-title":"Chimeric antigen receptor-modified T\u00a0cells for acute lymphoid leukemia","volume":"368","author":"Grupp","year":"2013","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2021.04.038_bib3","doi-asserted-by":"crossref","first-page":"224ra25","DOI":"10.1126\/scitranslmed.3008226","article-title":"Efficacy and toxicity management of 19-28z CAR T\u00a0cell therapy in B cell acute lymphoblastic leukemia","volume":"6","author":"Davila","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymthe.2021.04.038_bib4","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T\u00a0cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2021.04.038_bib5","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","article-title":"T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial","volume":"385","author":"Lee","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.ymthe.2021.04.038_bib6","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1056\/NEJMoa1709919","article-title":"Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia","volume":"378","author":"Park","year":"2018","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2021.04.038_bib7","doi-asserted-by":"crossref","first-page":"2767","DOI":"10.1038\/s41375-019-0615-5","article-title":"CD19 chimeric antigen receptor-T cells in B-cell leukemia and lymphoma: current status and perspectives","volume":"33","author":"Mohty","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.ymthe.2021.04.038_bib8","doi-asserted-by":"crossref","first-page":"303ra139","DOI":"10.1126\/scitranslmed.aac5415","article-title":"Chimeric antigen receptor T\u00a0cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia","volume":"7","author":"Porter","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymthe.2021.04.038_bib9","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1200\/JCO.2014.56.2025","article-title":"Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T\u00a0cells expressing an anti-CD19 chimeric antigen receptor","volume":"33","author":"Kochenderfer","year":"2015","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.ymthe.2021.04.038_bib10","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","article-title":"Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas","volume":"377","author":"Schuster","year":"2017","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2021.04.038_bib11","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2021.04.038_bib12","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.ymthe.2020.10.022","article-title":"Clinical Perspective: Treatment of Aggressive B Cell Lymphomas with FDA-Approved CAR-T Cell Therapies","volume":"29","author":"Leick","year":"2021","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2021.04.038_bib13","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1158\/1078-0432.CCR-11-1920","article-title":"The future is now: chimeric antigen receptors as new targeted therapies for childhood cancer","volume":"18","author":"Lee","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ymthe.2021.04.038_bib14","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/imr.12131","article-title":"Design and development of therapies using chimeric antigen receptor-expressing T\u00a0cells","volume":"257","author":"Dotti","year":"2014","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.ymthe.2021.04.038_bib15","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.blre.2015.10.003","article-title":"Chimeric antigen receptor T\u00a0cell therapy: 25 years in the making","volume":"30","author":"Gill","year":"2016","journal-title":"Blood Rev."},{"key":"10.1016\/j.ymthe.2021.04.038_bib16","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1172\/JCI85309","article-title":"CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients","volume":"126","author":"Turtle","year":"2016","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.ymthe.2021.04.038_bib17","doi-asserted-by":"crossref","first-page":"3479","DOI":"10.1172\/JCI86437","article-title":"BET bromodomain inhibition enhances T\u00a0cell persistence and function in adoptive immunotherapy models","volume":"126","author":"Kagoya","year":"2016","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.ymthe.2021.04.038_bib18","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1038\/s41375-020-0874-1","article-title":"Cytokine IL-36\u03b3 improves CAR T-cell functionality and induces endogenous antitumor response","volume":"35","author":"Li","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.ymthe.2021.04.038_bib19","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1038\/nri1632","article-title":"NFAT proteins: key regulators of T-cell development and function","volume":"5","author":"Macian","year":"2005","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.ymthe.2021.04.038_bib20","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1038\/nri.2017.52","article-title":"The non-canonical NF-\u03baB pathway in immunity and inflammation","volume":"17","author":"Sun","year":"2017","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.ymthe.2021.04.038_bib21","doi-asserted-by":"crossref","first-page":"121322","DOI":"10.1172\/jci.insight.121322","article-title":"4-1BB enhancement of CAR T function requires NF-\u03baB and TRAFs","volume":"3","author":"Li","year":"2018","journal-title":"JCI Insight"},{"key":"10.1016\/j.ymthe.2021.04.038_bib22","doi-asserted-by":"crossref","first-page":"3381","DOI":"10.4049\/jimmunol.157.8.3381","article-title":"Differential activation of the ERK, JNK, and p38 mitogen-activated protein kinases by CD40 and the B cell antigen receptor","volume":"157","author":"Sutherland","year":"1996","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.ymthe.2021.04.038_bib23","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/nrc.2017.121","article-title":"Targeting B cell receptor signalling in cancer: preclinical and clinical advances","volume":"18","author":"Burger","year":"2018","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ymthe.2021.04.038_bib24","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1002\/eji.1830250515","article-title":"Signaling via major histocompatibility complex class II molecules and antigen receptors enhances the B cell response to gp39\/CD40 ligand","volume":"25","author":"Bishop","year":"1995","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.ymthe.2021.04.038_bib25","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.4049\/jimmunol.169.3.1145","article-title":"Cutting edge: molecular mechanisms of synergy between CD40 and the B cell antigen receptor: role for TNF receptor-associated factor 2 in receptor interaction","volume":"169","author":"Haxhinasto","year":"2002","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.ymthe.2021.04.038_bib26","doi-asserted-by":"crossref","first-page":"2575","DOI":"10.1074\/jbc.M310628200","article-title":"Synergistic B cell activation by CD40 and the B cell antigen receptor: role of B lymphocyte antigen receptor-mediated kinase activation and tumor necrosis factor receptor-associated factor regulation","volume":"279","author":"Haxhinasto","year":"2004","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ymthe.2021.04.038_bib27","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.jim.2016.01.007","article-title":"Assessment of costimulation and coinhibition in a triple parameter T\u00a0cell reporter line: simultaneous measurement of NF-\u03baB, NFAT and AP-1","volume":"430","author":"Jutz","year":"2016","journal-title":"J.\u00a0Immunol. Methods"},{"key":"10.1016\/j.ymthe.2021.04.038_bib28","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.ymthe.2018.11.015","article-title":"Chimeric Antigen Receptor Library Screening Using a Novel NF-\u03baB\/NFAT Reporter Cell Platform","volume":"27","author":"Rydzek","year":"2019","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2021.04.038_bib29","doi-asserted-by":"crossref","first-page":"3153","DOI":"10.1158\/1078-0432.CCR-13-0330","article-title":"Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T\u00a0cells","volume":"19","author":"Hudecek","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ymthe.2021.04.038_bib30","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.ccell.2015.09.004","article-title":"Structural Design of Engineered Costimulation Determines Tumor Rejection Kinetics and Persistence of CAR T Cells","volume":"28","author":"Zhao","year":"2015","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ymthe.2021.04.038_bib31","first-page":"5866","article-title":"Neutrophils contribute to the biological antitumor activity of rituximab in a non-Hodgkin\u2019s lymphoma severe combined immunodeficiency mouse model","volume":"9","author":"Hernandez-Ilizaliturri","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ymthe.2021.04.038_bib32","doi-asserted-by":"crossref","first-page":"eaay8248","DOI":"10.1126\/scisignal.aay8248","article-title":"4-1BB costimulation promotes CAR T\u00a0cell survival through noncanonical NF-\u03baB signaling","volume":"13","author":"Philipson","year":"2020","journal-title":"Sci. Signal."},{"key":"10.1016\/j.ymthe.2021.04.038_bib33","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1038\/s41375-019-0417-9","article-title":"Constitutively active MyD88\/CD40 costimulation enhances expansion and efficacy of chimeric antigen receptor T\u00a0cells targeting hematological malignancies","volume":"33","author":"Collinson-Pautz","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.ymthe.2021.04.038_bib34","doi-asserted-by":"crossref","first-page":"136093","DOI":"10.1172\/jci.insight.136093","article-title":"MyD88\/CD40 signaling retains CAR T\u00a0cells in a less differentiated state","volume":"5","author":"Prinzing","year":"2020","journal-title":"JCI Insight"},{"key":"10.1016\/j.ymthe.2021.04.038_bib35","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1158\/2326-6066.CIR-19-0115","article-title":"Metabolic Consequences of T-cell Costimulation in Anticancer Immunity","volume":"7","author":"Teijeira","year":"2019","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.ymthe.2021.04.038_bib36","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/S0092-8674(02)00767-5","article-title":"Transcriptional mechanisms underlying lymphocyte tolerance","volume":"109","author":"Maci\u00e1n","year":"2002","journal-title":"Cell"},{"key":"10.1016\/j.ymthe.2021.04.038_bib37","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.immuni.2007.09.006","article-title":"Molecular signature of CD8+ T\u00a0cell exhaustion during chronic viral infection","volume":"27","author":"Wherry","year":"2007","journal-title":"Immunity"},{"key":"10.1016\/j.ymthe.2021.04.038_bib38","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.immuni.2015.01.006","article-title":"The transcription factor NFAT promotes exhaustion of activated CD8+ T\u00a0cells","volume":"42","author":"Martinez","year":"2015","journal-title":"Immunity"},{"key":"10.1016\/j.ymthe.2021.04.038_bib39","doi-asserted-by":"crossref","first-page":"2476","DOI":"10.1038\/sj.onc.1204386","article-title":"Partners in transcription: NFAT and AP-1","volume":"20","author":"Maci\u00e1n","year":"2001","journal-title":"Oncogene"},{"key":"10.1016\/j.ymthe.2021.04.038_bib40","doi-asserted-by":"crossref","first-page":"aab4077","DOI":"10.1126\/science.aab4077","article-title":"Remote control of therapeutic T\u00a0cells through a small molecule-gated chimeric receptor","volume":"350","author":"Wu","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2021.04.038_bib41","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.cell.2017.01.016","article-title":"The Principles of Engineering Immune Cells to Treat Cancer","volume":"168","author":"Lim","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.ymthe.2021.04.038_bib42","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/mt.2009.210","article-title":"Chimeric antigen receptors combining 4-1BB and CD28 signaling domains augment PI3kinase\/AKT\/Bcl-XL activation and CD8+ T\u00a0cell-mediated tumor eradication","volume":"18","author":"Zhong","year":"2010","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2021.04.038_bib43","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1182\/blood-2011-07-366419","article-title":"Generation of CD19-chimeric antigen receptor modified CD8+ T\u00a0cells derived from virus-specific central memory T\u00a0cells","volume":"119","author":"Terakura","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2021.04.038_bib44","doi-asserted-by":"crossref","first-page":"10995","DOI":"10.1158\/0008-5472.CAN-06-0160","article-title":"CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in\u00a0vivo persistence and antitumor efficacy of adoptively transferred T\u00a0cells","volume":"66","author":"Kowolik","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.ymthe.2021.04.038_bib45","doi-asserted-by":"crossref","first-page":"911","DOI":"10.4049\/jimmunol.1402346","article-title":"Target antigen density governs the efficacy of anti-CD20-CD28-CD3 \u03b6 chimeric antigen receptor-modified effector CD8+ T\u00a0cells","volume":"194","author":"Watanabe","year":"2015","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.ymthe.2021.04.038_bib46","doi-asserted-by":"crossref","first-page":"4262","DOI":"10.1172\/JCI84813","article-title":"Targeted antibody-mediated depletion of murine CD19 CAR T\u00a0cells permanently reverses B cell aplasia","volume":"126","author":"Paszkiewicz","year":"2016","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.ymthe.2021.04.038_bib47","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1158\/2326-6066.CIR-16-0043","article-title":"A Tet-On Inducible System for Controlling CD19-Chimeric Antigen Receptor Expression upon Drug Administration","volume":"4","author":"Sakemura","year":"2016","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.ymthe.2021.04.038_bib48","doi-asserted-by":"crossref","first-page":"2980","DOI":"10.1182\/blood-2015-12-686725","article-title":"Phase 1 studies of central memory-derived CD19 CAR T-cell therapy following autologous HSCT in patients with B-cell NHL","volume":"127","author":"Wang","year":"2016","journal-title":"Blood"}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001621002525?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001621002525?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T20:05:38Z","timestamp":1778616338000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001621002525"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":48,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["S1525001621002525"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2021.04.038","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Composite CD79A\/CD40 co-stimulatory endodomain enhances CD19CAR-T cell proliferation and survival","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2021.04.038","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}]}}